Sanofi's Genzyme rare diseases division already sells ... which remains the only other FDA-approved therapies for Pompe. The company estimates there are around 3,500 people in the US with both ...

Sanofi paid out $315 million to former Genzyme shareholders in that case, well below the $700 million to $3.8 billion range promised in the CVR. The FDA has started a priority review of Bristol ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced several management changes and additions. The ...

Researchers found increased odds for clinical remission on dupilumab with high blood eosinophil and fractional exhaled nitric ...

L Becquemont received consulting fees from Sanofi-Aventis, Pfizer and Servier, and lecture fees from Genzyme, GlaxoSmithKline, Bristol-Myers Squibb and Merck Sharp and Dohme. His wife works for ...

Histamine receptor, a typical G-protein-coupled receptor (GPCR), is important mediator of signalling and is responsible for regulation of human autoimmunity. Here, the authors report an artificial ...

After hours: February 28 at 7:43:36 PM EST Loading Chart for DNLI ...

Novartis announced today it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Allergy Asthma and ...

Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, ...

After hours: 7:43:36 p.m. EST Loading Chart for DNLI ...